US/UK/Canada

Share

About Us

Curasight is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and treatment in multiple cancer types, most notably for brain and prostate cancer.

Quotes

We believe our theranostic approach using the uPAR target could provide improved diagnosis and more gentle treatment options for patients in the future. The rights issue will give us an important injection of capital that will enable us to pursue our updated strategy of developing uTRACE and uTREAT in parallel.
Ulrich Krasilnikoff, CEO Curasight
Pick a time period -
Tags ( Active)

Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT[®] in Aggressive Brain Cancer (Glioblastoma)

Copenhagen, 8 June 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTREAT[®] in patients with aggressive brain cancer (glioblastoma). A preliminary readout of the Phase 1 clinical trial with uTREAT[®] in glioblastoma, an aggressive brain cancer, has now been undertaken. The data support:   · The feasibility and safety of the mode of administration, super-selective intra-arterial cerebral injection (super-SIACI) with local, transient opening of the blood-brain barrier (BBB) using

Interim report Q1 2026

Copenhagen, Denmark, 28 May 2026 - Curasight A/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, hereby publishes the interim report Q1 2026. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “Q1 2026 marked continued progress across both our therapeutic uTREAT® and diagnostic uTRACE® platforms as we advanced our integrated theranostic

Major Shareholding Notification - share transfer and ownership restructuring – related party transaction

Copenhagen, 26 April 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the company has received notification that AK 2014 Holding ApS, Krasilnikoff Holding ApS and UK Curacap ApS have merged their holding of shares in Curacap II ApS. This announcement is published in accordance with the applicable major shareholding notification rules of Spotlight Stock Market.Background It is hereby announced that a change in the shareholding structure of a technical nature has been completed following an internal restructuring between existing major shareholders. Co-

Resolutions of the Annual General Meeting 2026 of Curasight A/S

Copenhagen, Denmark, 25 March 2026 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its Annual General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, DenmarkToday, the shareholders in Curasight passed the following resolutions at the Annual General Meeting in accordance with the agenda: 1. The Board of Directors’ report on the Company’s activities in the past financial year The general meeting took note of the Board of Directors’ report on the Company’s activities in 2025. 2. Presentation and approval of the annual report

Notice of Annual General Meeting 2026

March 25, 2026 The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) on Wednesday 25 March 2026 at 10.00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.Agenda 1. The Board of Directors’ report on the Company’s activities in the preceding financial year  2. Presentation and approval of the annual report 3. Resolution on appropriation of profit or covering of loss as recorded in the annual report 4. Election of members to the Board of

Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade

Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) issued a convertible loan note to Fenja Capital II A/S (“Fenja Capital”) on 29 December 2025, with a nominal amount of DKK 25 million. Fenja Capital has now exercised its right to partially convert the convertible loan, whereby a total of 429,363 new ordinary shares has been issued at a conversion price of DKK 9,975 per share, corresponding to a nominal value of approximately DKK 4.3 million. In connection with the conversion, all of the converted shares have been sold by Fenja Capital in a block transaction executed between Fenja

Annual Report 2025

Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand therapy platform  across multiple aggressive solid tumors, hereby publishes the Annual Report 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “2025 was a transformative year for Curasight. We transitioned from platform validation to active clinical execution by dosing the first patient in our Phase

Year-end report Q4 2025

Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS), a clinical-stage radiopharmaceutical company pioneering a first-in-class uPAR-targeted radioligand therapy platform  addressing multiple aggressive solid tumors, hereby publishes the Year-end report Q4 2025. The Year-end report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “Q4 2025 marked strong momentum, as we advanced the company to become a clinical-stage therapeutic company pioneering uTREAT® - our first-

Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston

COPENHAGEN, Denmark, February 17, 2026 - Curasight A/S (TICKER:CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, will present recent company progress including the ongoing Phase 1 clinical trial uTREAT® in glioblastoma, at the TD Cowen 46[th] Annual Health Care Conference on Tuesday, March 3[rd], 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston.A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on

Major Shareholding Notification

Copenhagen, 9 February 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the company has received notification that Pentwater Capital Management LP, 1001 10th Avenue South, Naples, FL 34102, on 3. February 2026 has reduced its holding of shares in the Company.Prior to the transaction, the shareholder held 5.29% of the share capital and voting rights in the Company. Following the transaction, the shareholder holds now 4.85%, corresponding to an ownership interest below 5%. This announcement is published in accordance with the applicable major shareholding

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[®] in High-Grade Gliomas

· Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma) · Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors  Copenhagen, 12[th] January, 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion,

Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Copenhagen, 5 January 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain types of cancers, announced that CEO Ulrich Krasilnikoff and CMO prof. Andreas Kjær will be in San Francisco during the 44[th] J.P. Morgan Healthcare Conference being held January 12-15, 2026.During the week, Curasight management will hold meetings with investors and other industry stakeholders. The meetings will include updates on the Company’s clinical progress, including the recent initiation of a Phase 1 trial with

Curasight A/S resolves to issue a convertible loan note

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) has, as previously communicated on 12 December 2025, entered into a loan agreement

Resolutions of the Extraordinary General Meeting December 2025

Copenhagen, 29 December 2025 – Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) today held its Extraordinary General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, DenmarkToday, the shareholders in Curasight passed the following resolutions at the Extraordinary General Meeting in accordance with the agenda: 1. Proposals from the Board of Directors 1.1 Authorisation to the Board of Directors to issue one or more convertible loan notes. The general meeting adopted the proposal to authorise the Board of Directors to issue one or more

Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[®] in Brain Cancer

· Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT® belonging to Curasight’s treatment platform · No patient safety issues were reported · The dosing marks a key milestone with Curasight now in clinical development with both its therapeutic (uTREAT®) and diagnostic (uTRACE®) platforms Copenhagen, 18 December 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer (high grade gliomas). The news marks the

Notice of Extraordinary General Meeting

The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company”) to an Extraordinary General Meeting on 29 December 2025 at 10:00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.Agenda 1. Proposals from the Board of Directors 1. 1.1 Authorisation to the Board of Directors to issue one or more convertible loan notes 1.2 Authorisation to the chairman of the meeting Complete proposals 1. Proposals from the Board of Directors The Board of Directors makes the proposals in items 1.1 and 1.2.

Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) has, in accordance with the intention announced by the Company through a press release,

Curasight A/S announces its intention to carry out a directed issue of shares and enter into a new loan facility

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) hereby announces its intention to carry out a directed issue of shares of a minimum of

Curasight to present at HC Andersen Capital

Copenhagen, Denmark, 28 November 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO professor Andreas Kjær will present the Q3 2025 Interim report and the company’s latest progress and strategy at HC Andersen Capital.The presentations will include an update on the business progress made by the company during the first three quarters of 2025 and look ahead at the expected coming news flow. Management will give an overall update on the company’s pipeline based on the proprietary uPAR theranostics platform and focused on

Interim report Q3 2025

Copenhagen, Denmark, 27 November 2025 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby publishes the interim report Q3 2025. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “During the third quarter of 2025 and period after, Curasight continued to make significant clinical and strategic progress as we advance our mission to improve outcomes for patients with serious cancers through precision diagnostics and targeted radionuclide therapy.

Curasight’s uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment

· Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT® · Site given green light by European Medicines Agency (EMA) and is now open for patient enrollment – first patient dosing expected Q4 2025 · Both arms of Curasight’s theranostic approach investigating better treatment (uTREAT®) and diagnosis (uTRACE®) of certain cancers are now in clinical development Copenhagen, 26 November 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced its phase 1 trial

Curasight to present at Dansk Aktionærforening InvestorDagen

Copenhagen, Denmark, 13 November 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff will present the company’s latest progress and strategy at Dansk Aktionærforening InvestorDagen in Copenhagen on Monday, 17th November 2025.Management will provide an overall update on the company’s pipeline based on Curasight’s  proprietary uPAR theranostics platform which is aimed at improving diagnosis and treatment of certain types of cancers including prostate and brain cancer. The presentation will also highlight key near-term milestones

Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting

· Part 1 of the trial is completed   · Part 2 recruitment well underway; completion expected in the first half of 2026 · The Phase 2 study in prostate cancer is part of the agreement between Curium Inc. and Curasight signed in May 2023 Copenhagen, Denmark, 29 October 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today strong momentum in part 2 of the Phase 2 Study investigating the company’s diagnostic platform uTRACE® in prostate cancer. All nine sites across Germany, Sweden and Denmark are now fully activated and recruiting patients following the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe